Global Gout Therapeutics Market Size study, by Drug Class, by Disease Condition, by Distribution Channel and Regional Forecasts 2022-2032

Description

Global Gout Therapeutics Market is valued approximately at USD 2.65 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.25% over the forecast period 2024-2032. Gout, an inflammatory arthritis condition resulting from the deposition of monosodium urate crystals in joints and tissues, is characterized by severe pain, swelling, and redness, often affecting the big toe. The market for gout therapeutics is experiencing significant growth, driven by various factors including the increasing prevalence of gout worldwide, advancements in research and development, and growing awareness of early diagnosis and management of the condition.

The rising prevalence of gout is particularly notable in developed countries, attributed to aging populations, sedentary lifestyles, unhealthy diets, and the prevalence of obesity and hypertension. Continuous R&D efforts focused on developing innovative and effective gout therapeutics are further propelling market growth. Pharmaceutical companies are actively working on novel drug formulations, targeted therapies, and regenerative medicine approaches to address the unmet needs of gout patients. This includes new medications targeting specific pathways involved in gout pathogenesis and exploring biologics and gene therapies.

North America held the largest share of the global gout therapeutics market in 2021 and is projected to remain highly lucrative during the forecast period. The region's growth is driven by the high incidence of gout and associated comorbidities in the U.S., where gout is the most common inflammatory arthritis. Studies indicate that more than nine million Americans suffer from gout, with a significant portion undergoing oral urate-lowering therapies. Meanwhile, the Asia Pacific region is expected to witness rapid market growth from 2022 to 2031, spurred by increasing incidence and prevalence of gout, coupled with heightened research and development activities in gout diagnosis and treatment.

Major market players included in this report are:

Takeda Pharmaceutical Company Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
AstraZeneca plc
Horizon Therapeutics plc
Merck & Co. Inc.
Teijin Pharma Ltd.
GlaxoSmithKline, Plc.
Zydus Group
Takeda Pharmaceuticals

The detailed segments and sub-segment of the market are explained below:

By Drug Class:

NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents
Others

By Disease Condition:

Acute Gout
Chronic Gout

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Chapter 1. Global Gout Therapeutics Market Executive Summary

1.1. Global Gout Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Disease Condition
- 1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Gout Therapeutics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Gout Therapeutics Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing prevalence of gout worldwide
- 3.1.2. Advancements in research and development
3.2. Market Challenges
- 3.2.1. Complexity in supply chain
- 3.2.2. Generic competition impacting profitability
3.3. Market Opportunities
- 3.3.1. Growing awareness of early diagnosis and management
- 3.3.2. Development of new therapies and treatment methods

Chapter 4. Global Gout Therapeutics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Gout Therapeutics Market Size & Forecasts by Drug Class 2022-2032

5.1. Segment Dashboard
5.2. Global Gout Therapeutics Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. NSAIDs
- 5.2.2. Corticosteroids
- 5.2.3. Colchicine
- 5.2.4. Urate-Lowering Agents
- 5.2.5. Others

Chapter 6. Global Gout Therapeutics Market Size & Forecasts by Disease Condition 2022-2032

6.1. Segment Dashboard
6.2. Global Gout Therapeutics Market: Disease Condition Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Acute Gout
- 6.2.2. Chronic Gout

Chapter 7. Global Gout Therapeutics Market Size & Forecasts by Distribution Channel 2022-2032

7.1. Segment Dashboard
7.2. Global Gout Therapeutics Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital Pharmacy
- 7.2.2. Retail Pharmacy
- 7.2.3. Online Pharmacy

Chapter 8. Global Gout Therapeutics Market Size & Forecasts by Region 2022-2032

8.1. North America Gout Therapeutics Market
- 8.1.1. U.S. Gout Therapeutics Market
  - 8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Disease Condition breakdown size & forecasts, 2022-2032
  - 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Gout Therapeutics Market
8.2. Europe Gout Therapeutics Market
- 8.2.1. U.K. Gout Therapeutics Market
- 8.2.2. Germany Gout Therapeutics Market
- 8.2.3. France Gout Therapeutics Market
- 8.2.4. Spain Gout Therapeutics Market
- 8.2.5. Italy Gout Therapeutics Market
- 8.2.6. Rest of Europe Gout Therapeutics Market
8.3. Asia-Pacific Gout Therapeutics Market
- 8.3.1. China Gout Therapeutics Market
- 8.3.2. India Gout Therapeutics Market
- 8.3.3. Japan Gout Therapeutics Market
- 8.3.4. Australia Gout Therapeutics Market
- 8.3.5. South Korea Gout Therapeutics Market
- 8.3.6. Rest of Asia Pacific Gout Therapeutics Market
8.4. Latin America Gout Therapeutics Market
- 8.4.1. Brazil Gout Therapeutics Market
- 8.4.2. Mexico Gout Therapeutics Market
- 8.4.3. Rest of Latin America Gout Therapeutics Market
8.5. Middle East & Africa Gout Therapeutics Market
- 8.5.1. Saudi Arabia Gout Therapeutics Market
- 8.5.2. South Africa Gout Therapeutics Market
- 8.5.3. Rest of Middle East & Africa Gout Therapeutics Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Takeda Pharmaceutical Company Ltd.
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Novartis AG
- 9.3.3. Regeneron Pharmaceuticals Inc.
- 9.3.4. AstraZeneca plc
- 9.3.5. Horizon Therapeutics plc
- 9.3.6. Merck & Co. Inc.
- 9.3.7. Teijin Pharma Ltd.
- 9.3.8. GlaxoSmithKline, Plc.
- 9.3.9. Zydus Group
- 9.3.10 Takeda Pharmaceuticals

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes